AKESF
Price
$17.25
Change
-$0.25 (-1.43%)
Updated
Sep 24 closing price
Capitalization
16.08B
NUVL
Price
$79.05
Change
+$1.53 (+1.97%)
Updated
Sep 26, 01:06 PM (EDT)
Capitalization
5.59B
41 days until earnings call
Interact to see
Advertisement

AKESF vs NUVL

Header iconAKESF vs NUVL Comparison
Open Charts AKESF vs NUVLBanner chart's image
AKESO
Price$17.25
Change-$0.25 (-1.43%)
Volume$150
Capitalization16.08B
Nuvalent
Price$79.05
Change+$1.53 (+1.97%)
Volume$364
Capitalization5.59B
AKESF vs NUVL Comparison Chart in %
Loading...
AKESF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKESF vs. NUVL commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKESF is a Hold and NUVL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (AKESF: $17.25 vs. NUVL: $77.52)
Brand notoriety: AKESF and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKESF: 3% vs. NUVL: 62%
Market capitalization -- AKESF: $16.08B vs. NUVL: $5.59B
AKESF [@Biotechnology] is valued at $16.08B. NUVL’s [@Biotechnology] market capitalization is $5.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKESF’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • AKESF’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, AKESF is a better buy in the long-term than NUVL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKESF’s TA Score shows that 4 TA indicator(s) are bullish while NUVL’s TA Score has 4 bullish TA indicator(s).

  • AKESF’s TA Score: 4 bullish, 5 bearish.
  • NUVL’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AKESF is a better buy in the short-term than NUVL.

Price Growth

AKESF (@Biotechnology) experienced а +1.47% price change this week, while NUVL (@Biotechnology) price change was -4.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.01%. For the same industry, the average monthly price growth was +9.06%, and the average quarterly price growth was +48.80%.

Reported Earning Dates

NUVL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKESF($16.1B) has a higher market cap than NUVL($5.59B). AKESF YTD gains are higher at: 146.429 vs. NUVL (-0.971).
AKESFNUVLAKESF / NUVL
Capitalization16.1B5.59B288%
EBITDAN/A-362.01M-
Gain YTD146.429-0.971-15,082%
P/E Ratio25.37N/A-
RevenueN/A0-
Total CashN/A1.01B-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
AKESFNUVL
RSI
ODDS (%)
Bearish Trend 1 day ago
54%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
77%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
43%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
49%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
63%
Bearish Trend 1 day ago
78%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
AKESF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USBOX24.99N/A
N/A
Pear Tree Quality Ordinary
MCSMX12.10N/A
N/A
Matthews China Small Companies
MGGPX38.15N/A
N/A
Morgan Stanley Inst Global Opp A
FIQEX78.29N/A
N/A
Fidelity Advisor Canada Z
RNWFX94.79-0.75
-0.79%
American Funds New World R5

AKESF and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKESF has been loosely correlated with INBX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AKESF jumps, then INBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKESF
1D Price
Change %
AKESF100%
N/A
INBX - AKESF
45%
Loosely correlated
+7.22%
SMMT - AKESF
27%
Poorly correlated
-1.17%
NUVL - AKESF
25%
Poorly correlated
-2.54%
BNTX - AKESF
23%
Poorly correlated
-1.67%
CPMV - AKESF
22%
Poorly correlated
-0.01%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XENE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-2.54%
XENE - NUVL
60%
Loosely correlated
-0.19%
CGON - NUVL
58%
Loosely correlated
-0.55%
CRNX - NUVL
57%
Loosely correlated
+2.02%
IDYA - NUVL
57%
Loosely correlated
+0.08%
NRIX - NUVL
56%
Loosely correlated
-4.25%
More